Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic ra… Read more
Market Cap & Net Worth: Clarity Pharmaceuticals Ltd (CLRPF)
Clarity Pharmaceuticals Ltd (PINK:CLRPF) has a market capitalization of $360.87 Million ($360.87 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #14498 globally and #5795 in its home market, demonstrating a -35.33% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Clarity Pharmaceuticals Ltd's stock price $0.97 by its total outstanding shares 372030071 (372.03 Million).
Clarity Pharmaceuticals Ltd Market Cap History: 2023 to 2025
Clarity Pharmaceuticals Ltd's market capitalization history from 2023 to 2025. Data shows growth from $479.92 Million to $360.87 Million (24.71% CAGR).
Clarity Pharmaceuticals Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Clarity Pharmaceuticals Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CLRPF by Market Capitalization
Companies near Clarity Pharmaceuticals Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Clarity Pharmaceuticals Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Clarity Pharmaceuticals Ltd Historical Marketcap From 2023 to 2025
Between 2023 and today, Clarity Pharmaceuticals Ltd's market cap moved from $479.92 Million to $ 360.87 Million, with a yearly change of 24.71%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $360.87 Million | -76.34% |
| 2024 | $1.53 Billion | +217.83% |
| 2023 | $479.92 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Clarity Pharmaceuticals Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $360.87 Million USD |
| MoneyControl | $360.87 Million USD |
| MarketWatch | $360.87 Million USD |
| marketcap.company | $360.87 Million USD |
| Reuters | $360.87 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.